Adaptation and early implementation of the PREdiction model for gene mutations (PREMM₅™) for lynch syndrome risk assessment in a diverse population

Kathleen F. Mittendorf1, Chinedu Ukaegbu2,3, Marian J. Gilmore1, Nangel M. Lindberg4, Tia L. Kauffman1, Donna J. Eubanks4, Elizabeth Shuster4, Jake Allen4, Carmit McMullen4, Heather Spencer Feigelson5, Katherine P. Anderson6, Michael C. Leo4, Jessica Ezzell Hunter1, Sonia Okuyama Sasaki6, Jamilyn M. Zepp1, Sapna Syngal2,3,7, Benjamin S. Wilfond8,9, Katrina A. B. Goddard1

Received: 30 October 2020 / Accepted: 4 March 2021 / Published online: 23 March 2021 © The Author(s) 2021

Abstract

Lynch syndrome (LS) is the most common inherited cause of colorectal and endometrial cancers. Identifying individuals at risk for LS without personal cancer history requires detailed collection and assessment of family health history. However, barriers exist to family health history collection, especially in historically underserved populations. To improve LS risk assessment in historically underserved populations, we adapted the provider-facing PREdiction Model for gene Mutations (PREMM₅™ model), a validated LS risk assessment model, into a patient-facing electronic application through an iterative development process involving expert and patient stakeholders. We report on preliminary findings based on the first 500 individuals exposed to the adapted application in a primary care population enriched for low-literacy and low-resource patients. Major adaptations to the PREMM₅™ provider module included reduction in reading level, addition of interactive literacy aids, incorporation of family history assessment for both maternal and paternal sides of the family, and inclusion of questions about individual relatives or small groups of relatives to reduce cognitive burden. In the first 500 individuals, 90% completed the PREMM₅™ independently; of those, 94% did so in 5 min or less (ranged from 0.2 to 48.8 min). The patient-facing application was able to accurately classify 84% of patients as having clinically significant or not clinically significant LS risk. Our preliminary results suggest that in this diverse study population, most participants were able to rapidly, accurately, and independently complete an interactive application collecting family health history assessment that accurately assessed for Lynch syndrome risk.

Keywords Family history · Hereditary cancer · Risk assessment · Lynch syndrome · Underserved

Kathleen F. Mittendorf and Chinedu Ukaegbu have contributed equally.

Kathleen F. Mittendorf
kathleen.f.mittendorf@kpchr.org

1 Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA
2 Dana Farber Cancer Institute, Boston, MA, USA
3 Harvard Medical School, Boston, MA, USA
4 Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA
5 Institute for Health Research, Kaiser Permanente, Denver, CO, USA
6 Denver Health and Hospital Authority, Denver, CO, USA
7 Brigham and Women’s Hospital, Boston, MA, USA
8 Treuman Katz Center for Pediatric Bioethics, Seattle Children’s Research Institute and Hospital, Seattle, WA, USA
9 Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
Introduction

Lynch syndrome (LS) is the most common hereditary cause of colorectal cancer (CRC), accounting for about 2–3% of all CRC [1–5]. Individuals with LS have increased lifetime risk of colorectal and endometrial cancers and increased risk for other malignancies such as stomach, small bowel, pancreas, ovarian, brain and urinary tract cancers [6]. Despite this increased risk, early identification of patients with LS allows for regular surveillance and risk-reduction procedures that can lead to decreased cancer incidence and mortality [6, 7]. While increasing awareness of hereditary cancer syndromes has led to more genetic predisposition testing for hereditary cancers, much of the increase in demand appears to be driven by testing for the more well-known hereditary breast and ovarian cancer syndrome (BRCA1 and BRCA2), while referral and testing for Lynch syndrome has remained relatively constant [8, 9]. Currently, the vast majority of individuals who carry LS mutations (MLH1, MSH2, MSH6, PMS2, and EPCAM) remain undiagnosed [9, 10]. As such, tools that facilitate LS identification are needed.

While systematic efforts to improve LS detection through universal tumor screening of patients with LS cancers exist, diagnosis of LS in the cancer-free population relies on a multi-step process initiated by the identification of a close relative with LS or a concerning family history. Insufficient family health history assessment and provider discomfort with obtaining family history negatively impacts the evaluation of hereditary cancer risk [11–13]. As a result, many individuals with LS mutations remain unidentified among the cancer-free population [11–13]. Family health history information about cancer has often been limited to first-degree relatives and may miss key details such as type of cancer and/or age at diagnosis [14–16]. Even when family health history is collected accurately and completely, appropriate genetics services referrals still may not take place [17].

In addition to barriers to obtaining accurate family health history, there are disparities in provision of referral for hereditary cancer genetic evaluation in historically underserved populations, leaving these individuals even less likely to have an appropriate risk assessment [18–22]. Emerging research shows that health information technology applications that utilize patient-entered family health history information can improve identification of individuals at-risk for hereditary cancers or other genetic conditions [23, 24]. Yet despite the promise of this research, significant barriers remain for equitable access to precision health care and personalized medicine, especially for historically underserved populations [19, 20, 22, 25–28].

To address the important issue of LS identification in cancer-free individuals, especially from historically underserved groups, we are conducting the Cancer Health Assessments Reaching Many (CHARM, NCT03426878) study as part of the Clinical Sequencing Evidence-Generating Research consortium [29]. This study is working to improve family health history-based access to genetic services for hereditary cancer syndromes. We used an iterative process to adapt a validated provider-facing risk assessment algorithm for LS—the PREdiction Model for gene Mutations-5 (or PREMM5™ model) [30], into a patient-facing electronic application. This tool was originally designed to help healthcare providers obtain a streamlined family history to identify individuals who should undergo genetic evaluation for LS. The adaptation process in the CHARM study included feedback from Patient Advisory Councils (PACs) and tool refinement by a large team of multidisciplinary healthcare delivery experts. We have now implemented this application in a primary care population enriched with individuals from medically underserved communities, and here we describe (1) the process and outcomes of the adaptation of the PREMM5™ model into a patient-facing application and (2) the initial implementation of the PREMM5™ patient application in two large healthcare settings reaching racially and ethnically diverse and low-socioeconomic status populations. If successful, the PREMM5™ patient application could be incorporated into primary care, reducing the barriers to successful identification of individuals at risk for LS.

Methods

Study overview

CHARM is testing a novel cancer genetics care delivery paradigm in predominantly healthy populations ages 18–49 years in the primary care setting. As part of the study, individuals are assessed for eligibility for genetic testing using validated hereditary cancer risk assessment algorithms.

Study setting

The setting included two healthcare delivery systems, Kaiser Permanente Northwest (KPNW) and Denver Health (DH), which have distinct clinical populations. KPNW is a vertically integrated system serving approximately 607,000 members in Northwest Oregon and Southwest Washington. We recruited patients scheduled to see providers located at two KPNW clinics with a higher proportion of patients who are racially or ethnically diverse and/or live in census tracts with > 20% of residents below the federal poverty level or have > 20% of residents with less than a high school education, henceforth referred to under the umbrella term
Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5™)...

“underserved populations.” DH is an integrated safety-net health system with nine Federally Qualified Health Centers based in Denver, Colorado. DH serves approximately 160,000 patients in Denver County, 69% of whom are racial and ethnic minorities, 81% of whom are publicly insured or uninsured, and 77% of whom live at or below 200% of the federal poverty level.

While we sought to recruit a disproportionately higher number of medically underserved populations, all English- or Spanish-speaking patients ages 18–49 years from both KPNW and DH health systems were eligible to take the risk assessment. The KPNW Institutional Review Board (IRB) approved this study and all collaborating IRBs ceded to KPNW except Dana Farber Cancer Institute and Columbia University, who approved the study separately.

Adapting the PREMM5™ provider web-based module into a patient-facing electronic application

Patient advisory committees (PAC)

DH and KPNW healthcare providers identified patients potentially interested in participating in CHARM’s Patient Advisory Committees (PAC). We recruited seven DH patients whose primary language was English to provide input on the English version of the PREMM5™ patient application (English-language PAC). Five of the seven English-language PAC members were from racial or ethnic minority groups. For the Spanish-language PAC, we recruited a group of 10 native Spanish speakers: three from DH and seven from a single KPNW clinic that primarily serves Spanish-speaking patients.

Iterative adaptation

The adaptation team included a Spanish-language and health literacy expert, two original developers of the PREMM5™ model, multiple healthcare delivery experts, a software engineer, and a user interface/experience design expert. The adaptation team developed the English patient-facing PREMM5™ application using the provider-facing PREMM5™ web-based module and the patient-facing PREMM1,2,6 electronic application implemented in a community practice setting [30, 31]. Initial adjustments were made for literacy level and health literacy by the health literacy expert. Following this input, the software design team created wireframe models of skip logic and graphical aids. The English adaptation team, English-language PAC, and CHARM study team iteratively reviewed these adapted materials (Fig. 1) [32]. During three PAC meetings and individual cognitive interviews, English-language PAC members provided feedback regarding the explanation of the purpose of the risk assessment, adapted question and results wording, layout of the tool, and made recommendations for where literacy aids would be helpful. The Spanish-language PAC provided input on Spanish translation wording and additional needs of the Spanish-speaking population in three rounds of individual cognitive interviews (Fig. 1). A separate manuscript will describe the PAC process and contributions to the CHARM study as a whole.

A patient-facing integrated version of the Breast Cancer Genetics Referral Screening Tool (B-RST™ 3.0) for individuals of limited literacy was developed in a parallel process that will be reported elsewhere [33–35]. In the CHARM eligibility assessment, the PREMM5™ and B-RST™ 3.0 applications were combined into a single sequence with a novel third module which evaluated limited family history (Fig. 2). Importantly, this sequence began with a set of questions inquiring about the patient’s personal and/or family history of cancer; responses to these initial questions determined to which specific risk assessment questions individuals were exposed. For individuals with a personal and/or family history of cancer, they are exposed to the B-RST™ 3.0 and PREMM5™ applications in a randomized fashion.
B-RST™ 3.0 consists of questions regarding the personal and family (first- and second-degree relatives’) history of breast cancer and ovarian cancer, as well as Ashkenazi Jewish ancestry. PREMM5™ consists of questions regarding personal and family (first- and second-degree relatives’) history of colon cancer, endometrial cancer, and the following LS-associated cancers: ovarian, stomach, small intestine, urinary tract/bladder/kidney, bile duct, brain, and pancreatic, as well as sebaceous gland skin tumors. The novel limited family history module asks about patient history of adoption, patient knowledge of cancer on the paternal/maternal sides, and the number of female relatives living beyond the age of 45 on each side. This module also screens for past history of genetic testing for LS or hereditary breast and ovarian cancer.

**Identification and enrollment**

**Participant identification and mailings**

At KPNW, we used electronic medical records to identify patients with upcoming appointments at participating clinic sites and recruited them via email and text message and set up in-clinic recruitment booths at two KPNW clinic sites, beginning in August 2018. At DH, patients who were identified as at potentially higher risk via the electronic medical record were recruited via postcard, follow up phone calls, and provider referral; patients at potentially higher risk were defined as (1) receiving cancer screening outside of general population screening guidelines, (2) having a hereditary breast and ovarian cancer syndrome- or LS-related cancer diagnosis before age 50, (3) documentation of family history of cancers related to either syndrome, or (4) receiving a referral for cancer-related genetics services but no documentation of genetic testing. This method was chosen as the starting recruitment approach at DH to facilitate patient receipt of genetic testing in this low-resource setting. Recruitment at DH began in October 2018. Preliminary results from the first 500 individuals encountering the PREMM5™-specific portion of the CHARM eligibility assessment and the first 124 individuals receiving genetic test results through the study are reported herein. Recruitment in Spanish began in February 2019, due to the phased implementation of translation and Spanish-language PAC review, as well as study resource requirements for programming the Spanish-language electronic tools.

**Eligibility assessment and consent process**

Interested patients could access CHARM eligibility assessment and study consent via the study webpage on their personal electronic device or, if assessment was completed at the clinic, on a clinic-provided tablet. Optional bilingual (English/Spanish) support for individuals completing the risk assessment was available in-person in the clinic, or over the phone. Following consent for the risk assessment, the application presented initial questions about personal or family cancer history. If the individual reported either personal or family history of cancer, the PREMM5™ assessment and the B-RST™ 3.0 assessment were presented in random order (Fig. 2). If individuals reported no personal or family history to the initial questions, they were only presented with additional questions assessing family structure and family history knowledge. A negative screen on both the PREMM5™ assessment and the B-RST™ 3.0 assessment also resulted in assessment of family structure and knowledge.

**Study enrollment and multi-step consent process for genetic testing**

The PREMM5™ application provided immediate feedback about LS risk and a report about indications for genetic testing in the case of a clinically significant PREMM5™ risk score (≥ 2.5%). Participants electing to receive genetic testing through the study completed a baseline survey and received genetic testing results during a post-test telephone genetic counseling session. Individuals who were eligible for genetic testing but declined to enroll in the study received an optional decliner survey. The baseline and decliner surveys included questions on years of formal education and English fluency, and the baseline survey assessed numeracy.
using a validated subjective numeracy measure, the three-
item subjective numeracy scale (SNS-3). Responses have
a summed range of 3–18, with higher scores representing
higher numeracy [36]. We report numeracy as an impor-
tant measure, because the PREMM5™ application requires
patients to add relatives together (e.g., number of brothers,
sisters, and children with colorectal cancer) and to choose
the youngest affected relative among that subgroup.

Collection of quality metrics

The total population included in our report was 517 indi-
viduals. These included the first 500 participants exposed
to PREMM5™-specific questions with complete data, and
17 additional individuals included in the validity analysis.

Time to completion

Our automated tracking system recorded the individual’s
language of choice, time of PREMM5™ answer input,
answers to specific questions, and the actual PREMM5™
scores for both sides of the family. For the first 500 individu-
als exposed to PREMM5™-specific questions and who com-
pleted the entire CHARM risk assessment, time to complete
the PREMM5™ portion of the application was computed as
the time participants spent on PREMM5™-specific ques-
tions. In the same population of the first 500 individuals
exposed to PREMM5™-specific questions, the number of
incomplete CHARM risk assessment encounters is separa-
ately reported, along with total time spent on the entirety
of the CHARM risk assessment and the PREMM5™ portion,
though participants may have terminated interaction during
completion of the PREMM5™ portion.

Comparison to genetic counselor-collected family history

In accordance with the adaptation of the Centers for Dis-
ease Control ACCE framework adaptation recommended
for evaluating family history tools, we assessed the pre-
liminary analytic validity (how well it measures the family
history that it intends to collect in comparison to a gold
standard family health history collection) of the PREMM5™
patient-facing application using data gathered by genetic
counselors as the comparator [37–41]. Genetic counselors
recorded structured family health history data in a REDCap
database from pedigrees constructed during the post-test
genetic counseling session, and also independently com-
puted and recorded a participant PREMM5™ score using the
PREMM5™ provider-facing tool on the basis of the genetic
counselor-determined affected side of the family.

We compared overall score computed by the patient-
facing application to overall score determined by the
genetic counselors, using the age at the time of results
disclosure. We included all patients with available genetic
counseling data (N = 124 at the time of analysis) in the
analysis, including (1) those who were not exposed to
PREMM5™-specific questions and/or did not have a score
based on patient-input (i.e. they reported having no
personal or family history of LS cancers on the patient-
facing application) but who did have a genetic counsel-
order-computed score (i.e. they subsequently reported LS family
history of LS cancers to the genetic counselor) and (2)
those who had a score based on patient-input but for whom
genetic counselors determined that there was no family
history of LS cancers. Assuming a minimum acceptable
value (H0) of a CCC of 0.80 [42] and a one-tailed alpha
value of 0.05, a sample size of 124 provides at least 83%
power if the true (H1) CCC is 0.87 or higher. We con-
ducted the power analysis using PASS 15 (PASS 15 Power
Analysis and Sample Size Software (2017). NCSS, LLC.
Kaysville, Utah, USA, ncss.com/software/pass.) In group
(1), we included patients who interacted with the shared
questions about overall personal or family history of can-
cer and were pathed directly to the limited family his-
tory questions (were not exposed to PREMM5™-specific
questions), as they could represent false negatives. The
PREMM5™ risk score was synthetically set to 0 in the
case of no reported LS personal or family history in order
to include both of these subsets of patients in the analy-
sis and to differentiate the extent of the difference in the
participant self-report and genetic counselor-computed
risk scores. We evaluated the agreement between the
PREMM5™ and genetic counselor calculation using Lin’s
concordance correlation coefficient [43].

Scores on the PREMM5™ patient application and by
 genetic counselor calculation that were both ≥ 2.5% (the
clinically significant risk score) were considered true posi-
tives. True negatives were considered non-clinically signifi-
cant scores on both the patient application and by genetic
counselor calculation. False positives were considered clin-
ically significant scores on the patient application but not by
genetic counselor calculation, and false negatives were non-
clinically significant scores on the patient application but
clinically significant scores by the genetic counselor calcula-
tion. An a priori definition of ≥ 5% absolute value difference
between the genetic counselor-computed score and the score
based on participant input was considered highly discrepant.

To determine whether sociodemographic characteristics
were predictive of whether or not someone was one of the
124 individuals in the mutually exclusive subset from the
500 individuals included in the analyses of time spent on
PREMM5™, we used logistic regression with the except-
ton of language which was evaluated via a Fisher’s exact
test. We performed separate analyses for each socio-demo-
graphic characteristic on the outcome of subset membership.
All inferential tests were evaluated a two-tailed alpha level

 Springer
of 0.05, but focused mainly on the magnitude based on the odds ratio.

Results

Iterative adaptation of the provider web-based PREMM$_5$™ module

The adaptation team advocated three major changes to the provider web-based PREMM$_5$™ module: (1) to not rely upon the patient to determine the affected side of the family (i.e., the side of the family with LS cancers); (2) to inquire about relatives one at a time or in small groups, rather than asking the patient about first and second-degree relatives, to reduce the demand for high numeracy; (3) to embed literacy aids [31].

In order to successfully implement adaptations (1) and (2) in a patient-friendly manner, user-experience design experts developed skip logic and a layout that presented only a few questions per screen and employed responsive design elements, to allow for ease of implementation on a variety of patient devices, ranging from desktop to handheld smartphones. Initial questions asked patients if they had a personal or family history of cancer, and in the event of a family history of cancer, the patients answered a second set of questions to narrow down the family members affected by cancer on both sides of the family (Fig. 3a; Supplementary Fig. 1a). For individuals identified as having a personal or family history of cancer, the specific LS-related cancer history questions were then presented (Fig. 3b; Supplementary Fig. 1b). To implement the final recommendation (3), the study team embedded hyperlinks to pop-up windows within the interactive application (Fig. 3c; Supplementary Fig. 1c; Supplementary Figure 2).

The PAC provided several suggestions about wording and literacy aids, often providing new phrases to describe biological concepts such as using the phrase “cancer in your family tree” to replace “hereditary cancer” or “inherited cancer” in the explanation and consent for the risk assessment. The PAC also suggested that we clarify “sebaceous gland skin tumors” to minimize it being confused with other more common types of skin cancer. In response, the study team embedded a pop-up literacy aid to describe that cancer (Supplementary Figure 2). The PAC suggested using a family tree graphic (Fig. 3c; Spanish translation in Supplementary Figure IC) to explain biological relatives and recommended the addition of the term “blood relatives.” Finally, the PAC suggested that an explanation of LS be added to the results page (Supplementary Figure 3) and that the study recommend genetic testing if the participant had a clinically-significant risk. However, due to IRB restrictions, the study team was unable to incorporate this suggestion. The Spanish-language PAC provided feedback and recommended, for example, that the tool provide examples of biological relatives and include the clarification that first cousins or in-laws should not be considered as biological relatives.

Fig. 3 Sample images from the patient-facing PREMM$_5$™ application. a Sample screen inquiring about cancer history in individual relatives or small groups of relatives. b Sample screen inquiring about cancer history in the mother, which appears if the participant selects that the mother had cancer. c Sample literacy aid pop-up window depicting the family tree graphic, which appears if the participant selects the modal link titled “Who are my blood relatives?” on the screen in A. The pop-up literacy aid for sebaceous gland skin tumors that appears when the patient selects the modal link in B is depicted in Supplementary Fig. 2a.
To support the changes to the tool described above, the PREMM₅™ output for the patient application algorithm was adapted to compute both a maternal and paternal PREMM₅™ score, to assign the affected side of the family computationally, and to report the participant PREMM₅™ result on the basis of the assigned affected side [30]. A comparison of the provider web-based PREMM₅™ module and the patient-facing application developed in CHARM is presented in Table 1.

### Participation and demographics

We assessed the first 500 individuals to encounter the adapted PREMM₅™-specific questions in English (n = 486) or Spanish (n = 14) and evaluated the accuracy of family health history information collected for all study participants that had completed their genetic counseling result disclosure visit at the time of analysis (n = 124) with genetic counselor-collected family health history data. Demographic characteristics are summarized in Table 2 and Supplementary Table 1, and the flow of the total population of participants through the risk assessment is presented in Supplementary Fig. 4.

Most participants (93%; n = 466) interacted with the risk assessment outside of the clinic, while a small proportion (7%, n = 34) did so in clinic; however, 12% (14/115) of DH participants completed the assessment in clinic while 4% (20/385) of KP participants did so, likely reflecting the difference in recruitment approaches at the two sites. A minority (3%, n = 14) selected Spanish-language as their language of choice, likely reflecting the delayed implementation of the Spanish-language option for the risk assessment. Of the individuals using the Spanish version, 79% (11/14) interacted with the risk assessment in clinic compared to 5% (23/486) of individuals using the English version.

Ninety five percent (n = 476) of individuals who encountered the PREMM₅™-specific questions went on to complete the entire CHARM risk assessment, and of those individuals who completed the assessment, 95% (n = 452) did so without assistance. Of the assisted individuals (N = 24), 29% (N = 7) were documented to have utilized study staff assistance over the phone and 71% (N = 17) utilized study staff assistance in person. Of the 24 assisted individuals, nearly all (96%; n = 23) met the study recruitment definition of an underserved population and a significant proportion (46%, n = 11) were individuals who took the risk assessment in Spanish; 79% of the individuals who took the risk assessment in Spanish utilized assistance compared to only 3% of individuals using the English version. Of those individuals exposed to PREMM₅™-specific questions who did not complete the full CHARM risk assessment, 29% (n = 7) were from a historically underserved population, as defined by the study, compared to 58% (n = 276) from a historically

---

| Feature | Question Presentation | Affect side of family | Number of questions | Skip logic | Family health history assessment | Clarification/literacy aids | Language | Similarities |
|---------|----------------------|----------------------|--------------------|------------|--------------------------------|---------------------------|---------|--------------|
| PREMM₅™ provider module | One scrolling screen | Provider selects the affected side of the family | 9–18, depending on provider answers | Limited | Assesses the affected sides of family members | On-screen definitions | Assumes provider literacy level; English only | Responsive design (can be used on all devices) |
| PREMM₅™ patient application | Few questions per screen | Removed requirement to select an affected side of the family | 2–46, depending on patient answers | Extensively utilized to streamline the user’s experience | Relatives assessed in family history (e.g., children, brothers, sisters) | Embedded definitions and infographics: further explanation of medical terms (e.g., sebaceous gland tumors) | Reduced literacy language (removed terms such as “unrelated relatives”); English and Spanish | Responsive design (can be used on all devices) |
underserved population among those who completed the risk assessment.

**PREMM$_5$™ patient application completion**

We examined the time participants spent on PREMM$_5$™-specific questions. Ninety four percent (n = 423) of individuals who independently completed the CHARM risk assessment spent 5 min or less on PREMM$_5$™-specific questions. The average time spent to complete the PREMM$_5$™ application was 2.3 min (SD = 3.6; ranged from 0.2 to 48.8 min). Only two participants took longer than 30 min to complete the PREMM$_5$™-specific questions. On average, participants were exposed to 13 (SD = 3; ranged from 2 to 29) PREMM$_5$™-specific questions.

It is possible that participants who did not complete the CHARM risk assessment may have spent a longer time on the risk assessment and/or on the PREMM$_5$™ portion. We evaluated the overall time spent on the CHARM risk assessment, as well as the time on PREMM$_5$™ alone, for
all sessions where the CHARM risk assessment was not completed. Considering all incomplete CHARM risk assessments with exposure to PREMM5™-specific questions, 82% of sessions had a CHARM risk assessment exposure duration lasting five or fewer minutes, while 89% of the PREMM5™-specific exposure durations lasted five or fewer minutes.

**Preliminary comparison of patient-reported family history to family history collected by genetic counselors**

At the time of analysis, 124 participants had completed their post-test genetic counseling session with a genetic counselor through the CHARM study, 108 of whom were exposed to PREMM5™-specific questions and 16 of whom pathed directly to the limited family history module due to lack of reported personal or family history of cancer. The associations of sociodemographic characteristics with whether or not an individual was included only in the time and completion analyses are presented in Supplementary Table 1; that application language is predictive of inclusion in the validity analysis was expected based on lack of availability of the Spanish language tool at study start. Among these 124 participants, 20 participants (16%) were mis-categorized from participant-generated PREMM5™ risk scores in comparison to genetic counselor-computed PREMM5™ risk scores, and were all deemed false positives, including 10 who were determined to have no LS-related cancer history. Participant-generated PREMM5™ risk scores identified all participants who had clinically significant genetic counselor-computed PREMM5™ scores, as such there were no false negatives in the subset of participants examined. Notably, 25% (31) of the participants examined had a clinically significant PREMM5™ risk score on the patient-facing application, with or without qualifying scores on the other CHARM risk assessment algorithms, while 75% (93) qualified for genetic testing on the basis of the other risk algorithms only. Four participants did not input personal LS cancer history but were determined to have personal LS cancer history by the genetic counselor but achieved clinically insignificant PREMM5™ scores.

Comparing the risk score difference between genetic counselor-computed PREMM5™ risk scores and those derived from participant input, participant completed family health history is more likely to overreport family history compared to the genetic counselor-collected family history. In the original assessment of agreement including all 124 data points, the concordance correlation coefficient was 0.51, 95% CI [0.40, 0.63]. However, there were two extreme multivariate outliers (absolute value difference in scores ≥ 15%). Upon removing those outliers, the concordance correlation coefficient was 0.86, 95% CI [0.82, 0.91] (Fig. 4), indicating that these were extremely influential observations and thus the inclusion of these points mask the true level of agreement observed for > 98% of the cases. Eight participants (6.5%) had patient-derived PREMM5™ scores with a score difference of 5% or greater compared to their genetic counselor-computed score, meeting our a priori score difference cut-off. The genetic counselor-computed PREMM5™ scores were lower than patient-derived PREMM5™ scores in seven of the eight participants, and all eight discrepant scores were due to varying magnitudes of misreported family health history in first- and second-degree relatives. Similarly, discernible patterns were not observable

**Fig. 4 Patient and provider differences in PREMM5™ risk scores.**

**a** Scatter plot of PREMM5™ scores derived from participant input and from genetic counselor-collected pedigrees. $r_c =$ concordance correlation coefficient after removal two of outliers (orange, square points). Concordance correlation coefficient with the two extreme outliers included was 0.51. Magenta box = inset. **b** Magnified view of magenta inset in Fig. 4a, demonstrating the trend toward participant overreport on the patient-facing tool when there was disagreement between measures, as well as the excellent agreement in the two measures for some participants (points on the line of perfect concordance).
in the 20 individuals with false positive risk scores, and more data will be needed to evaluate any trends that could be addressed by risk assessment modifications. Future work will include qualitative interviews with study participants to evaluate their perception of the PREMM$^5$™ assessment, including patient perceptions of reasons for misreport, and a detailed assessment of patterns found in relative type(s) or type(s) of cancer leading to patient misreport.

Discussion

With the goal of mitigating barriers to LS risk recognition and LS-related genetics services referral, we developed a patient-facing PREMM$^5$™ application. This application is designed to facilitate self-reported cancer family health history by patients at lower levels of health literacy in the primary care setting. Our preliminary results suggest that in a diverse study population, most participants were able to rapidly, accurately, and independently complete the application. These adaptations may offer an avenue to improve referral for LS-related genetics services.

Based on feedback from patient advisors, we included graphic and descriptive literacy aids to improve understanding and clarify difficult concepts. We also simplified the PREMM$^5$™ application to allow collection of relevant cancer family health history on both sides of the family and to ask about individual relatives or groups of relatives. Our preliminary results show that in our diverse population of study participants, most appear to be able to independently complete an interactive application collecting family health history pertaining to LS risk. Participants were also able to complete the application quickly, in an average of less than five minutes. Together, these results suggest that these adaptations were successful in terms of ease of completion. Given that a major barrier in health care is the identification of individuals at risk of hereditary cancer syndromes, a tool that can be quickly and easily completed by the patient could reduce this barrier to genetics services referral, especially in the primary care setting [11–13]. Systematically providing risk assessment to all patients in primary care may help reduce the known disparities in access to referral for hereditary cancer genetic evaluation in historically underserved populations [18–22]. However, it is important to note that of the participants completing the risk assessment but requiring assistance from a study staff member (5% of the study population), almost all (96%) met the study recruitment definition of underserved and 79% of Spanish speakers utilized assistance. As such, it would be important for care systems to provide some bilingual staffing for assistance in completing such applications, in order for the tool to be most equitably deployed. Such staff would not need to be highly trained.

It is recommended that patient-facing family health history tools are evaluated for their analytic validity (how well it measures the family history that it intends to collect in comparison to a gold standard family health history collection) and time to completion [37–40]. Yet, reviews of existing family health history tools show that few studies assess these components [37–39, 44–46]. A recent review of predominantly (78%) self-administered cancer family health history tools found that researchers reported time to completion for less than half (42%) of the 62 tools reviewed [37]. Of tools with time-to-completion reported, 77% took less than 30 min to complete, with the remaining tools taking between 33 min to 120 h (no data was provided on interruptions). Thus, in comparison to the literature, PREMM$^5$™ performs well in terms of time-to-completion.

While some studies have reported analytic validity of family health history tools, the methodologies vary [37]. Individuals with a concerning family health history may be missed by the risk assessment due to patient misunderstanding or misreport (false negatives) or individuals may over-report cancer history and be incorrectly classified as high risk (false positives). As such, we have utilized this as the primary metric to assess analytic validity. In our study, genetic counselors collected family health history from all patients who had genetic testing, regardless of whether they qualified via PREMM$^5$™, B-RST™ 3.0, or on the basis of existing family health history tools show that few studies assess these components [37–39, 44–46]. A recent review of predominantly (78%) self-administered cancer family health history tools found that researchers reported time to completion for less than half (42%) of the 62 tools reviewed [37]. Of tools with time-to-completion reported, 77% took less than 30 min to complete, with the remaining tools taking between 33 min to 120 h (no data was provided on interruptions). Thus, in comparison to the literature, PREMM$^5$™ performs well in terms of time-to-completion.

Looking more granularly at PREMM$^5$™ risk score differences between the participant-reported and genetic counselor-collected family health history, when excluding two extreme outliers, there appears to be modest agreement between the two measures (Fig. 4). This suggests that the patient-facing tool may approximate genetic counselor-collected risk assessments in many cases, but we observed a few cases of large disagreement that warrant further investigation. This investigation may allow us to isolate the source of disagreement and offer avenues to improve the tool. Additionally, we observed a trend toward overreport of family history on the patient-facing tool. It will be important to understand reasons for misreport and overreport on the patient-facing application to allow further improvement of the application, especially in terms of addressing whether the tool is equitable in diverse populations.
Limitations

Because recruitment occurs at KPNW primarily via email and text message with a link to the CHARM webpage, we likely oversampled participants who have internet access. The initial sample is also biased toward English-speaking participants, as the Spanish application was implemented six months after the English application, and female participants outnumber male participants, which is common in genetic studies [47, 48]. More data are needed to evaluate the success of the application in individuals who choose to complete the application in Spanish, since only 14 individuals had completed it at the time of this analysis, many utilized assistance, and none had yet completed genetic counseling. Additionally, the DH population was initially enriched for higher-risk individuals, which may impact the validity analyses. Thus, participants included in our initial sample may not be representative of historically underserved populations nor the study population once the study is completed, so a full validity assessment will be required at study end. Further analyses will be required with a greater number of patients to discern possible patterns of misreport. A detailed description of recruitment results and response rates for the CHARM study is planned at study completion.

The PAC feedback regarding the risk assessment consent was greatly modified by the primary site IRB [32]. Importantly, IRB input led to greatly increased literacy level of the consent for risk assessment. This is in line with the reported experience of studies in the Electronic Medical Records and Genomics (eMERGE) network, which also reported difficulty balancing providing detailed information about genomic studies as required by site IRBs, and the need for readability [49]. Future studies should take into account potential limitations of stakeholder work in the light of IRB-required elements of consent and develop processes with site IRBs to continue to improve the navigation of the important intersection of enhancing research participant diversity and protecting the interests of vulnerable populations.

While we have examined the ability of participant self-report on the PREMM₃™ patient-facing application to appropriately risk-stratify patients in comparison to a genetic counselor, this examination is biased toward participants who qualified for CHARM via one of three risk assessments and elected genetic testing. Thus, it is probable that the true sensitivity is lower than in this population; that is, there are additional false negatives in the population of individuals who did not qualify for genetic testing on any risk assessment, or who qualified but did not consent to genetic testing. Further, to make quantitative comparisons of PREMM₃™ risk scores, we had to approximate participants without an evaluable PREMM₃™ family health history input on the patient application or with no LS history as determined by the genetic counselor as having a PREMM₃™ risk score of 0, and genetic counselors utilized the age at result disclosure in the risk calculation, which in some cases may have been one year older, resulting in a slightly lower PREMM₃™ risk score.

Finally, family history data during genetic counseling should ideally be verified with participant and/or family member’s medical records, where possible [37–40]. Due to study limitations, this additional level of confirmation was not obtained, so the genetic counselor-recorded family history may recapitulate errors, such as misremembered ages, which would have greater chance of remedy in the traditional clinical model [38, 39].

Conclusions and Future Directions

Our preliminary data indicate that, in the diverse CHARM study population, most participants are able to quickly complete the PREMM₃™ patient-facing application. Early data suggest the PREMM₃™ application can appropriately risk-stratify most patients compared to genetic counselor-collected family health history. However, there are a few patients who have relatively large PREMM₃™ score differences, as well as patients who are inappropriately categorized. Participants typically overestimate the frequencies of LS-related cancers in their family on the patient-facing application. We plan to conduct a validity analysis with all patients at study end, to analyze patterns in misreport, and to examine the contribution of participant characteristics such as education, English fluency, and numeracy to the time participants spent on the application and to the accuracy of their family health history input. Future work will also include qualitative interviews with participants with variations in misreport. These evaluations will be used to refine the PREMM₃™ patient application to create an equitable assessment with higher specificity.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10689-021-00243-3.

Acknowledgements We acknowledge the entirety of the CHARM study team, including additional recruitment staff (Kristin Muessig, Ana Reyes, Briana Arnold, Sonia Deutsch, Elizabeth Medina, Rosse Rodriguez, and Chris Whitebirch) and genetic counselors (Brad Rolf and Laura Amendola) who collected data for this work, and the members of the English and Spanish PAC, who provided invaluable insight for the risk assessment modifications. We also acknowledge the CSER consortium. This manuscript was edited by Kevin Lutz at KPNW. Finally, we acknowledge Angela Paolucci and Ana Reyes of KPNW for formatting and submission assistance.

Author contributions KFM, CU, MJG, NML, CM, TLK, SS, JEH, HSF, KPA, SO, ML, and KAB contributed to study design. SCM and NML directed stakeholder engagement work. KFM, CU, TLK, DJE, JA, CM, NML, SS, and KAB contributed to PREMM₃™ adaptation.
and refinement. SS and CU are responsible for the original PREMM\textsuperscript{TM} model algorithm; CU, KFM, DJE, and SS contributed to algorithm adaptation to incorporate the novel questions and question order specific to the patient-facing application. KFM, CU, DJE, MJG, JZ, ML, and ES performed analysis and data interpretation. KM, CU, MJG, and NML wrote the first draft of the manuscript. All authors contributed to final interpretation of results and editing and approval of the final version of the manuscript.

**Funding** This work was funded as part of the Clinical Sequencing Evidence-Generating Research (CSER) consortium funded by the National Human Genome Research Institute with co-funding from the National Institute on Minority Health and Health Disparities (NIMHD) and the National Cancer Institute (NCI). The CSER consortium represents a diverse collection of projects investigating the application of genome-scale sequencing in different clinical settings including pediatric and adult subspecialties, germline diagnostic testing and tumor sequencing, and specialty and primary care. This work was supported by a grant from the National Human Genome Research Institute (U01HG007292: MPIs: Wilfond, Goddard), with additional support from U24HG007307 (Coordinating Center). Dr. Mittendorf was funded by a diversity supplement to U01HG007292. Additionally, National Cancer Institute Award Number R01CA132829 (Syngal) supported portions of work by SS and NIH T32 GM007748 supported CU.

**Compliance with ethical standards**

**Conflict of interest** PREMM\textsuperscript{TM} and all associated logos are trademarks\textsuperscript{TM} or registered\textsuperscript{®} trademarks of Dana Farber Cancer Institute, Inc. Dr. Syngal has served as a consultant for Myriad Genetics and DC Health Technologies, and has rights to an inventor portion of the licensing revenue from PREMM\textsuperscript{®}. All other authors report no conflict of interest.

**Ethical approval** The KPNW Institutional Review Board (IRB) approved this study and all collaborating IRBs ceded to KPWN except Dana Farber Cancer Institute and Columbia University, who approved the study separately.

**Consent to Participate** All study participants provided informed consent prior to study enrollment.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltohakki P, Chadwick RB, Kaarinaen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487. https://doi.org/10.1056/NEJM199805213382101
2. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamay A, Prior T, Westman JA, Panesu J, Fix D, Lockman J, LaJeuunesse J, Comeras I, de la Chapelle A (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788. https://doi.org/10.1200/JCO.2008.17.5950
3. Moreira L, Balaguer F, Lndor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz de Leon M, Rustgi AK, Castellis A, Consortium E (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308(15):1555–1565. https://doi.org/10.1001/jama.2012.13088
4. Vesna HF (2005) Clinical description of the Lynch syndrome (hereditary nonpolyposis colorectal cancer (HNPPC)). Fam Cancer 4(3):219–225. https://doi.org/10.1007/s10689-004-3906-5
5. Yurgelun MB, Kukle MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CB, Brii LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S (2017) Lynch syndrome susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 35(10):1086–1095. https://doi.org/10.1200/JCO.2016.71.0012
6. National Comprehensive Cancer Network (NCCN) (2019) Clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal V1.2019.
7. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macraf F, Blanco I, Siijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rodland EA, Thammaratnam K, Cappell WHDVTN, Hill J, Wijnen J, Green K, Laloo F, Sund L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkens-Sinisalo L, Frayling IM, Plazzer JP, Plavainane K, Sampson JR, Capella G, Mecklin JP, Moslein G, Mallorca G (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopy and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66(3):464–472. https://doi.org/10.1136/gutjnl-2015-309675
8. Casey N (2017) Lynch Syndrome is a common hereditary condition that can cause ovarian cancer—So why isn’t anybody talking about it? Health & Fitness
9. Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert F (2015) Lynch Syndrome is a common hereditary condition that can cause ovarian cancer—Why isn’t anybody talking about it? Health & Fitness
10. Institute. NC (2016) Cancer moonshot blue ribbon panel report
11. Nippert I, Harris HJ, Julian-Reynier C, Kristoffersson U, Ten Kate LP, Anionwu E, Benjamin C, Challen K, Schmidlke J, Nippert RP, Harris R (2011) Confidence of primary care physicians in their ability to carry out basic medical genetic tasks—a European survey in five countries—Part 1. J Community Genet 2(1):1–11. https://doi.org/10.1007/s10549-013-02669-9
12. Plat AW, Kroon AA, Van Schayck CP, De Leeuw PW, Stoffers HE (2009) Obtaining the family history for common, multifactorial diseases by family physicians. A descriptive systematic review. Eur J Gen Pract 15(4):231–242. https://doi.org/10.3109/1381780903447572
13. Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R (2018) Automatic genetic risk assessment by SS and NIH T32 GM007748 supported CU.
calculation using breast cancer family history data from the ehr compared to self-report. AMIA Annu Symp Proc 2018:970–978
14. Flynn BS, Wood ME, Ashikaga T, Stockdale A, Dana GS, Naud S (2010) Primary care physicians’ use of family history for cancer risk assessment. BMC Fam Pract 11:45. https://doi.org/10.1186/1471-2296-11-45
15. Murtif HJ, Byrne D, Syngal S (2004) Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med 27(3):239–245. https://doi.org/10.1016/j.amepre.2004.05.003
16. Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 32(8):824–829. https://doi.org/10.1200/JCO.2013.51.4661
17. Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH (2010) Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 115(5):945–952. https://doi.org/10.1097/AOG.0b013e3181dd08d7
18. Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, Pal T (2017) Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer 123(13):2497–2505. https://doi.org/10.1002/cncr.30621
19. Delkurt T, Williamson GR, Anastasiadou V, Skirton H (2015) A systematic review of factors that act as barriers to patient referral to genetic services. Eur J Human Genet: EJHG 23(6):739–745. https://doi.org/10.1038/ejhg.2014.180
20. McCarthy AM, Bristol M, Domchek SM, Groeneveld PW, Kim Y, Motanya UN, Shea JA, Armstrong K (2016) Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. J Clin Oncol 34(22):2610–2618. https://doi.org/10.1200/JCO.2015.66.0019
21. Shields AE, Burke W, Levy DE (2008) Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med 10(6):404–414. https://doi.org/10.1097/GIM.0b013e3181770184
22. Stamp MH, Gordon OK, Childers CP, Childers KK (2019) Painting a portrait: analysis of national health survey data for cancer genetic counseling. Cancer Med 8(3):1306–1314. https://doi.org/10.1002/cam4.1366
23. Murray MF, Giovannia MA, Klinger E, George E, Marinacci L, Getty G, Brawarsky P, Rocha B, Orav EJ, Bates DW, Haas JS (2013) Comparing electronic health record portals to obtain patient-entered family history health in primary care. J Gen Intern Med 28(12):1558–1564. https://doi.org/10.1007/s11606-013-2442-0
24. Wu RR, Himmel TL, Buchanan AH, Powell KP, Hauser ER, Ginsburg GS, Henrich VC, Orlando LA (2014) Quality of family history collection with use of a patient facing family history assessment tool. BMC Fam Pract 15:31. https://doi.org/10.1186/1471-2296-15-31
25. Cragun D, Kinney AL, Pal T (2017) Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing. Expert Rev Mol Diagn 17(1):57–70. https://doi.org/10.1080/14737159.2017.1267567
26. Green RF, Ari M, Kolor K, Dotson WD, Bowen S, Habarta N, Rodriguez JL, Richardson LC, Khoury MJ (2019) Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework. Genet Med 21(1):28–37. https://doi.org/10.1038/s41436-018-0028-2
27. Mathew SS, Barwell J, Khan N, Lynch E, Parker M, Qureshi N (2017) Inclusion of diverse populations in genomic research and health services: Genomix workshop report. J Community Genet 8(4):267–273. https://doi.org/10.1007/s12687-017-0317-5
28. Smith CE, Fullerton SM, Dookeran KA, Hampel H, Tin A, Maruthur NM, Schisler JC, Henderson JA, Tucker KL, Or dovaz JM (2016) using genetic technologies to reduce, rather than widen. Health Disparities Health Aff (Millwood) 35(8):1367–1373. https://doi.org/10.1377/hlthaff.2015.1476
29. Amendola LM, Berg JS, Horowitz CR, Angelo F, Bensen JT, Biesecker BB, Biesecker LG, Cooper GM, East K, Filipkis K, Fullerton SM, Gelb BD, Goddard KAB, Hailu B, Hart R, Has-smiller-Lich K, Joseph G, Kenny EJ, Koenig BA, Knight S, Kwok PY, Lewis KL, McGuire AL, Norton ME, Ou J, Parsons DW, Powell BC, Risch N, Robinson M, Rini C, Scollon S, Slavotinek AM, Veenstra DL, Wasserstein MP, Wilfond BS, Hindorff LA, Consortium C, Pton SE, Jakvik GP (2018) The clinical sequencing evidence-generating research consortium: integrating genomic sequencing in diverse and medically underserved populations. Am J Hum Genet 103(3):319–327. https://doi.org/10.1016/j.ajhg.2018.08.007
30. Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurge-lun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S (2017) Development and validation of the PREMM5 model for comprehensive risk assessment of lymph node disease. J Clin Oncol 35(19):2165–2172. https://doi.org/10.1200/JCO.2016.69.6120
31. Luba DG, DiSario JA, Rock C, Saraiya D, Moyes K, Brown K, Rushton K, Ogarra MM, Raphel M, Zimmerman D, Garrido K, Silguero E, Nelson J, Yurgelun MB, Kastrinos F, Wenstrup RJ, Syngal S (2018) Community practice implementation of a self-administered version of PREMM1,2,6 to assess risk for lymph node disease. Clin Gastroenterol Hepatol 16(1):49–58. https://doi.org/10.1016/j.cgh.2017.06.038
32. Kraft SA, McMullen C, Lindberg NM, Bui D, Shipman K, Anderson K, Joseph G, Duenas DM, Porter KM, Kaufman TL, Koomas A, Ransom CL, Jackson P, Goddard KAB, Wilfond BS, Lee SS (2020) Integrating stakeholder feedback in translational genomics research: an ethnographic analysis of a study protocol’s evolution. Genet Med 22(6):1094–1101. https://doi.org/10.1038/s41436-020-0763-z
33. Bellcross C (2010) Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Genet Med 12(4):240. https://doi.org/10.1007/GIM.0b013e3181d4bc3a
34. Bellcross C, Hershad M, Tallo C, Stanislaw C (2019) Validation of version 3.0 of the breast cancer genetics referral screening tool (B-RST). Genet Med 21(1):181–184. https://doi.org/10.1038/s41436-018-0020-x
35. Bellcross CA, Lemke AA, Page LS, Tess AL, Meisner LT (2009) Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 11(11):783–789. https://doi.org/10.1097/GIM.0b013e3181b9b04a
36. McNaughton CD, Cavanaugh KL, Kripalani S, Rothman RL, Wallston KA (2015) Validation of a short, 3-item version of the subjective numeracy scale. Med Decis Mak 35(8):932–936. https://doi.org/10.1177/0272989X15581800
37. Cleophat JE, Nabi H, Pelletier S, Bouchard K, Dorval M (2018) What characterizes cancer family history collection tools? A critical literature review. Curr Oncol (Toronto, Ont) 25(4):e335–e350. https://doi.org/10.3747/ico.25.4042
38. Qureshi N, Carroll JC, Wilson B, Santaguida P, Allanson J, Brouwers M, Raina P (2009) The current state of cancer family history collection tools in primary care: a systematic review. Genet Med 11(7):495–506. https://doi.org/10.1097/GIM.0b013e3181a7e8e0
39. Qureshi N, Wilson B, Santaguida P, Carroll J, Allanson J, Culebro CR, Brouwers M, Raina P (2007) Collection and use of cancer
family history in primary care. Evid Rep Technol Assess (Full Rep) 159:1–84

40. Valdez R, Yoon PW, Qureshi N, Green RF, Khoury MJ (2010) Family history in public health practice: a genomic tool for disease prevention and health promotion. Annu Rev Public Health 31:69–87. https://doi.org/10.1146/annurev.publhealth.012809.103621

41. Center for Disease Control’s (CDC) Office of public health genomics (OPHG). ACCE model process for evaluating genetic tests. https://www.cdc.gov/genomics/gtesting/acce/index.htm.

42. Ad G (1991) Practice statistics for medical research. Chapman and Hall, London

43. Lawrence IKL (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45(1):255–268. https://doi.org/10.2307/2532051

44. Welch BM, Wiley K, Pfieger L, Achiangia R, Baker K, Hughes-Halbert C, Morrison H, Schiffman J, Doerr M (2018) Review and comparison of electronic patient-facing family health history tools. J Genet Couns 27(2):381–391. https://doi.org/10.1007/s10897-018-0235-7

45. Laforest F, Kirkegaard P, Mann B, Edwards A (2019) Genetic cancer risk assessment in general practice: systematic review of tools available, clinician attitudes, and patient outcomes. Br J Gen Pract 69(679):e97–e105. https://doi.org/10.3399/bjgp18X700265

46. de Hoog CL, Portegijs PJ, Stoffers HE (2014) Family history tools for primary care are not ready yet to be implemented. A systematic review. Eur J Gen Pract 20(2):125–133. https://doi.org/10.3109/13814788.2013.840825

47. Gardner SA, Weymouth KS, Bogdanova E, Chen W, Lupu D, Suhl J, Zeng Q, Geigenmüller U, Boles D, Okamoto PM, McDowell G, Hayden MA, Nagan N (2018) Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory. Hered Cancer Clin Pract 16:1–1. https://doi.org/10.1186/s13053-017-0083-8

48. LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, Chen E, Gau CL, Palmer E, Shoaeipour K, Shah D, Speare V, Gandomi S, Chao E (2014) Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 16(11):830–837. https://doi.org/10.1038/gim.2014.40

49. Fossey R, Kochan D, Winkler E, Pacyna JE, Olson J, Thibodeau S, Connolly JJ, Harr M, Behr MA, Prows CA, Cobb B, Myers MF, Leslie ND, Namjou-Khales B, Milo Rasouly H, Wynn J, Fedotov A, Chung WK, Gharavi A, Williams JL, Pais L, Holm I, Aufox S, Smith ME, Scrol A, Leppig K, Jarvik GP, Wiesner GL, Li R, Stroud M, Smoller JW, Sharp RR, Kulko IJ (2018) Ethical considerations related to return of results from genomic medicine projects: the emerge network (Phase III) experience. J Pers Med. https://doi.org/10.3390/jpm8010002

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.